Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P68371
UPID:
TBB4B_HUMAN
Alternative names:
Tubulin beta-2 chain; Tubulin beta-2C chain
Alternative UPACC:
P68371; A2BFA2; P05217
Background:
Tubulin beta-4B chain, also known as Tubulin beta-2 chain and Tubulin beta-2C chain, plays a pivotal role in cell structure and function as the major constituent of microtubules. These microtubules are essential for various cellular processes, including cell division, intracellular transport, and maintenance of cell shape. The dynamic assembly of tubulin into microtubules involves the addition of GTP-tubulin dimers, facilitated by the GTPase activity of alpha-tubulin.
Therapeutic significance:
The Tubulin beta-4B chain is implicated in Leber congenital amaurosis with early-onset deafness, a severe autosomal dominant disorder affecting vision and hearing from the first decade of life. Understanding the role of Tubulin beta-4B chain could open doors to potential therapeutic strategies for this debilitating condition.